Macquarie Research **Equities**





INDIA

SUEL IN

Suzlon Energy

24 September 2009

Stock price as of 22 Sep 09 12-month target Upside/downside Valuation	Rs Rs % Rs	100.80 79.00 -21.6 79.00
- Sum of parts		
GICS sector		capital goods
Market cap	Rs m	156,918
30-day avg turnover	US\$m	31.2
Market cap	US\$m	3,272
Number shares on issue	m	1,557

Investment fundamentals

Year end 31 Mar		2009A	2010E	2011E	2012E
Total revenue	bn	260.8	258.9	302.8	340.2
EBITDA	bn	27.9	25.2	34.7	41.7
EBITDA growth	%	40.2	-9.7	37.5	20.3
Adjusted profit	bn	11.3	5.9	14.0	18.4
EPS adj	Rs	7.58	3.65	8.72	11.45
EPS adj growth	%	-4.1	-51.8	138.7	31.3
PE adj	x	13.3	27.6	11.6	8.8
Total DPS	Rs	1.18	1.10	1.10	1.15
Total div yield	%	1.2	1.1	1.1	1.1
ROA ROE EV/EBITDA Net debt/equity Price/book	% X % X	6.9 13.5 9.6 107.8 1.7	5.1 6.3 11.1 99.1 1.6	7.2 13.2 8.1 80.0 1.4	8.4 15.3 6.7 60.2 1.3

SUEL IN rel SENSEX performance, & rec history



Source: FactSet, Macquarie Research, September 2009 (all figures in INR unless noted)

Analysts

Inderjeetsingh Bhatia

91 22 6653 3166 inderjeet.bhatia@macquarie.com Somesh Agarwal

91 22 6653 3064 somesh.agarwal@macquarie.com

Risk-reward remains unfavourable

Event

Underperform

Promoters of Suzlon sold 69.5m shares at Rs96.85 each, raising around Rs6.95bn. These shares make up around 4.5% of the total paid-up capital. Given the possible downside for the core business and a possible delay in the sale of Hansen (HSN LN, £123, N, TP: £121, downside: 2%), we see the riskreward profile as unfavourable and rate Suzlon as an Underperform.

Impact

- Promoter stake sale does solve funding issues: Promoter stakes in the company have fallen from 57.6% to 53.1%. The promoters have indicated that funds would be infused into the listed company, most probably as unsecured debt for working capital and other funding requirements. However, we believe this only highlights that Suzlon's funding situation remains difficult. Moreover, 25.5% of the stake is still pledged.
- Delay in Hansen transaction another risk: The share price had started to build in expectations of an early sale of Suzlon's stake in Hansen, which would deleverage the balance sheet. However, with the promoter stake sale, it seems that the transaction will not be taking place in the near term.
- Downside risk to consensus estimates as US revival is likely to be much weaker: Our global renewable energy team recently cut its estimates for wind turbine installations in 2010, in their detailed report of 11 September 2009. We now forecast only 7% growth in 2010, in contrast to the consensus, which expects a sharp rebound (35% growth). We believe growth is likely to return to trajectory only in 2011. If these forecasts are borne out, they could have an impact on the timing and value of the Hansen transaction. Key reasons for the downgrade are listed below:
 - ⇒ In the US, the government's push in this area has weakened as some funds for the debt guarantee programme have been withdrawn.
 - ⇒ The availability of long-term power purchase agreements (PPAs) remains an issue.
 - ⇒ Grid connectivity is also hampering PPAs and limiting the availability of credit

Earnings and target price revision

No change.

Price catalyst

- 12-month price target: Rs79.00 based on a sum of parts methodology.
- Catalyst: Order inflow remaining weak; a delay in the Hansen transaction.

Action and recommendation

• Risk-reward remains unfavourable: The stock is trading at a premium of around 10% over global wind turbine companies. Given the risk to consensus estimates, the possible delay in the Hansen sale and continued promoter dilution, we maintain our Underperform call on the stock.

Please refer to the important disclosures and analyst certification on inside back cover of this document, or on our website www.macquarie.com.au/research/disclosures.

Suzion Energy (SUI	EI INI	Undernerform	Tarnet	nrica:	Re70	UU)

Suzion Energy (SUE Quarterly Results	EL IN, C	4Q/09A	1Q/10E	2Q/10E	3Q/10E	Profit & Loss		2009A	2010E	2011E	2012E
Revenue	m	65,204	64,734	64,734	64,734	Revenue	m	260,817	258,934	302,815	340,242
Gross Profit	m	17,648	12,979	12,979	12,979	Gross Profit	m	70,592	51,918	64,272	74,475
Cost of Goods Sold	m	47,556	51,754	51,754	51,754	Cost of Goods Sold	m	190,226	207,017	238,543	265,768
EBITDA	m	6,979	6,303	6,303	6,303	EBITDA	m	27,915	25,211	34,673	41,726
Depreciation	m	1,433 0	1,515 0	1,515 0	1,515 0	Depreciation	m	5,731 0	6,059 0	6,721 0	7,335 0
Amortisation of Goodwill Other Amortisation	m m	0	0	0	0	Amortisation of Goodwill Other Amortisation	m m	0	0	0	0
EBIT	m	5,546	4,788	4,788	4,788	EBIT	m	22,184	19,152	27,952	34,391
Net Interest Income	m	-2,635	-2,612	-2,612	-2,612	Net Interest Income	m	-10,539	-10,449	-9,635	-8,806
Associates	m	6	0	0	0	Associates	m	23	0	0	0
Exceptionals	m	-2,241	0	0	0	Exceptionals	m	-8,963	0	0	0
Forex Gains / Losses	m	0	0	0	0	Forex Gains / Losses	m	0	0	0	0
Other Pre-Tax Income	m	1,122	581	581	581	Other Pre-Tax Income	m	4,488	2,325	2,469	2,719
Pre-Tax Profit	m	1,798	2,757	2,757	2,757	Pre-Tax Profit	m	7,193	11,028	20,786	28,304
Tax Expense	m	-720	-870	-870	-870	Tax Expense	m	-2,881	-3,479	-4,274	-7,000
Net Profit Minority Interests	m m	1,078 -487	1,887 -420	1,887 -420	1,887 -420	Net Profit Minority Interests	m m	4,312 -1,947	7,549 -1,679	16,512 -2,498	21,304 -2,900
Reported Earnings Adjusted Earnings	m m	1,078 2,832	1,887 1,468	1,887 1,468	1,887 1,468	Reported Earnings Adjusted Earnings	m m	4,312 11,328	7,549 5,870	16,512 14,014	21,304 18,404
EPS (rep)		0.72	1.17	1.17	1.17	EPS (rep)		2.88	4.70	10.27	13.26
EPS (adj)		1.89	0.91	0.91	0.91	EPS (adj)		7.58	3.65	8.72	11.45
EPS Growth yoy (adj)	%	-4.1	-51.8	-51.8	-51.8	EPS Growth (adj)	%	-4.1	-51.8	138.7	31.3
						PE (rep)	х	35.0	21.5	9.8	7.6
						PE (adj)	Х	13.3	27.6	11.6	8.8
EBITDA Margin	%	10.7	9.7	9.7	9.7	Total DPS	0/	1.18	1.10	1.10	1.15
EBIT Margin	% %	8.5 25.0	7.4 25.0	7.4 25.0	7.4 25.0	Total Div Yield	% m	1.2 1,495	1.1 1,607	1.1 1,607	1.1 1,607
Earnings Split Revenue Growth	% %	25.0 90.7	25.0 -0.7	25.0 -0.7	25.0 -0.7	Weighted Average Shares Period End Shares	m m	1,495	1,607	1,607	1,607
EBIT Growth	%	30.5	-13.7	-13.7	-13.7	T Gliod Elid Gliales		1,400	1,007	1,007	1,007
Profit and Loss Ratios		2009A	2010E	2011E	2012E	Cashflow Analysis		2009A	2010E	2011E	2012E
Revenue Growth	%	90.7	-0.7	16.9	12.4	EBITDA	m	27,915	25,211	34,673	41,726
EBITDA Growth	%	40.2	-9.7	37.5	20.3	Tax Paid	m	0	0	0	0
EBIT Growth	%	30.5	-13.7	45.9	23.0	Chgs in Working Cap	m	0	0	0	0
Gross Profit Margin	%	27.1	20.1	21.2	21.9	Net Interest Paid	m	0	0	0	0
EBITDA Margin	%	10.7	9.7	11.5	12.3	Other	m	-63,435	-19,510	-21,664	-25,462
EBIT Margin	%	8.5	7.4	9.2	10.1	Operating Cashflow	m	-35,519	5,701	13,009	16,265
Net Profit Margin	% %	1.7	2.9	5.5	6.3	Acquisitions	m	31,367	12.020	4 160	4 4 2 7
Payout Ratio EV/EBITDA	% X	15.5 9.6	30.0 11.1	12.6 8.1	10.0 6.7	Capex Asset Sales	m m	-33,308 0	-12,920 0	-4,160 0	-4,127 0
EV/EBIT	X	12.1	14.6	10.0	8.1	Other	m	0	0	0	0
LV/LBIT	^	12.1	14.0	10.0	0.1	Investing Cashflow	m	-1,941	-12,920	-4,160	-4,127
Balance Sheet Ratios						Dividend (Ordinary)	m	-1,791	-1,791	-1,791	-1,885
ROE	%	13.5	6.3	13.2	15.3	Equity Raised	m	0	0	0	0
ROA	%	6.9	5.1	7.2	8.4	Debt Movements	m	49,325	-11,182	-11,182	-11,182
ROIC	%	11.0	5.8	8.9	10.3	Other	m	0	0	0	0
Net Debt/Equity Interest Cover	% x	107.8 2.1	99.1 1.8	80.0 2.9	60.2 3.9	Financing Cashflow	m	47,534	-12,973	-12,973	-13,067
Price/Book Book Value per Share	Х	1.7 57.7	1.6 62.3	1.4 69.9	1.3 80.2	Net Chg in Cash/Debt	m	10,074	-20,192	-4,123	-930
Book value per offare		51.1	02.5	03.3	00.2	Free Cashflow	m	-68,828	-7,219	8,850	12,137
						Balance Sheet		2009A	2010E	2011E	2012E
						Cash	m	30,698	13,656	14,529	19,398
						Receivables	m	53,928	53,206	58,074	65,252
						Inventories	m	71,737	78,105	87,540	97,704
						Investments	m	51	51	51	51
						Fixed Assets	m	61,044	67,905	65,344	62,137
						Intangibles	m	0	0	0	0
						Other Assets	m	158,057	167,424	172,233	176,334
						Total Assets Payables	m m	375,514 105,947	380,347 106,411	397,771 120,296	420,875 135,165
						Short Term Debt	m m	105,947	106,411	120,296	133,103 A
						Long Term Debt	m	148,696	137,514	126,332	115,150
						Provisions	m	9,576	9,576	9,576	9,576
						Other Liabilities	m	1,868	1,868	1,868	1,868
						Total Liabilities	m	266,087	255,369	258,072	261,758
						Shareholders' Funds	m	86,292	100,164	112,388	128,906
						Minority Interests	m	23,135	24,813	27,311	30,211
						Other	m	0	0	0	0 450 447
						Total S/H Equity Total Liab & S/H Funds	m m	109,427 375,514	124,978 380,347	139,699 397,771	159,117 420,875
All figures in INR unless note	ed.							•	,	,	, -
Source: Company data, Mac		search, Septe	mber 2009								
				· · · · · · · · · · · · · · · · · · ·					· · · · · · · · · · · · · · · · · · ·	· · · · · · · · · · · · · · · · · · ·	

24 September 2009 2

Important disclosures:

Recommendation definitions

Macquarie - Australia/New Zealand

Outperform – return >5% in excess of benchmark return Neutral – return within 5% of benchmark return Underperform – return >5% below benchmark return

Macquarie - Asia/Europe

Outperform – expected return >+10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

Macquarie First South - South Africa

Outperform – expected return >+10% Neutral – expected return from -10% to +10% Underperform – expected return <-10%

Macquarie - Canada

Outperform – return >5% in excess of benchmark return Neutral – return within 5% of benchmark return Underperform – return >5% below benchmark return

Macquarie - USA

Outperform (Buy) – return >5% in excess of benchmark return (Russell 3000)

Neutral (Hold) – return within 5% of benchmark return (Russell 3000)

Underperform (Sell)– return >5% below benchmark return (Russell 3000)

Recommendations - 12 months

Note: Quant recommendations may differ from Fundamental Analyst recommendations

Volatility index definition*

This is calculated from the volatility of historical price movements.

Very high-highest risk – Stock should be expected to move up or down 60–100% in a year – investors should be aware this stock is highly speculative.

High – stock should be expected to move up or down at least 40–60% in a year – investors should be aware this stock could be speculative.

Medium – stock should be expected to move up or down at least 30–40% in a year.

Low-medium – stock should be expected to move up or down at least 25–30% in a year.

 \boldsymbol{Low} – stock should be expected to move up or down at least 15–25% in a year.

* Applicable to Australian/NZ/Canada stocks only

Financial definitions

All "Adjusted" data items have had the following adjustments made:

Added back: goodwill amortisation, provision for catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests

EPS = adjusted net profit / efpowa*

ROA = adjusted ebit / average total assets
ROA Banks/Insurance = adjusted net profit /average
total assets

ROE = adjusted net profit / average shareholders funds Gross cashflow = adjusted net profit + depreciation *equivalent fully paid ordinary weighted average number of shares

All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards).

Recommendation proportions - For quarter ending 30 June 2009

	AU/NZ	Asia	RSA	USA	CA	EUR	
Outperform	40.38%	48.53%	40.00%	44.02%	57.42%	40.20%	(for US coverage by MCUSA, 1.54% of stocks covered are corporate advisory clients)
Neutral	39.25%	17.08%	45.00%	37.45%	32.90%	39.21%	(for US coverage by MCUSA, 1.16% of stocks covered are corporate advisory clients)
Underperform	20.38%	34.40%	15.00%	18.53%	9.68%	20.59%	(for US coverage by MCUSA, 0.77% of stocks covered are corporate advisory clients)

Company Specific Disclosures:

Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures.

Analyst Certification:

The views expressed in this research accurately reflect the personal views of the analyst(s) about the subject securities or issuers and no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst principally responsible for the preparation of this research receives compensation based on overall revenues of Macquarie Group Ltd ABN 94 122 169 279 (AFSL No. 318062)(MGL) and its related entities (the Macquarie Group) and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

General Disclaimers:

Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital Markets Canada Ltd; Macquarie Capital Markets North America Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Securities Ltd; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ) Ltd; and Macquarie First South Securities (Pty) Limited are not authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements (including the FSA Rules) which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise.

Country-Specific Disclaimers:

Canada: In Canada, securities research is prepared, approved and distributed by Macquarie Capital Markets Canada Ltd, a participating organisation of the Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. Macquarie Capital Markets North America Ltd., which is a registered broker-dealer and member of FINRA, accepts responsibility for the contents of reports issued by Macquarie Capital Markets Canada Ltd in the United States and to US persons and any person wishing to effect transactions in the securities described in the reports issued by Macquarie Capital Markets Canada Ltd should do so with Macquarie Capital Markets North America Ltd. Securities research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947) in Australia, a participating organisation of the Australian Securities Exchange; Macquarie Securities (NZ) Ltd in New Zealand, a licensed sharebroker and New Zealand Exchange Firm. The Research Distribution Policy of Macquarie Capital Markets Canada Ltd is to

24 September 2009 3

allow all clients that are entitled to have equal access to our research. United Kingdom: In the United Kingdom, securities research is issued and distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Services Authority (No. 193905). Hong Kong: In Hong Kong, securities research is issued and distributed by Macquarie Capital Securities Ltd in Hong Kong, which is licensed and regulated by the Securities and Futures Commission. Japan: In Japan, securities research is issued and distributed by Macquarie Capital Securities (Japan) Limited in Japan, a member of the Tokyo Stock Exchange, Inc., Osaka Securities Exchange Co. Ltd, and Jasdaq Securities Exchange, Inc. (Financial Instruments Firm, Kanto Financial Bureau (kin-sho) No. 231, a member of Japan securities Dealers Association and Financial Futures Association of Japan). South Africa: In South Africa, securities research is issued and distributed by Macquarie First South Securities (Pty) Limited in South Africa, a member of the JSE Limited. Singapore: In Singapore, securities research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. United States: In the United States, securities research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered broker-dealer and member of FINRA. Macquarie Capital (USA) Inc, accepts responsibility for the content of each research report prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Macquarie Capital (USA) Inc.'s affiliate's analysts are not registered as research analysts with FINRA, may not be associated persons of Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures, or contact your registered representative at 1-888-MAC-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Securities, 125 W.55th Street, New York, NY 10019. © Macquarie Group

Auckland Tel: (649) 377 6433	Bangkok Tel: (662) 694 7999	Calgary Tel: (1 403) 218 6650	Hong Kong Tel: (852) 2823 3588	Jakarta Tel: (62 21) 515 1818	Johannesburg Tel: (2711) 583 2000	Kuala Lumpur Tel: (60 3) 2059 8833
London Tel: (44 20) 3037 4400	Manila Tel: (63 2) 857 0888	Melbourne Tel: (613) 9635 8139	Montreal Tel: (1 514) 925 2850	Mumbai Tel: (91 22) 6653 3000	Perth Tel: (618) 9224 0888	Seoul Tel: (82 2) 3705 8500
Shanghai Tel: (86 21) 6841 3355	Singapore Tel: (65) 6231 1111	Sydney Tel: (612) 8232 9555	Taipei Tel: (886 2) 2734 7500	Tokyo Tel: (81 3) 3512 7900	Toronto Tel: (1 416) 848 3500	New York Tel: (1 212) 231 2500

Available to clients on the world wide web at www.macquarieresearch.com and through Thomson Financial, FactSet, Reuters, Bloomberg, CapitalIQ and TheMarkets.com.

24 September 2009 4

Macquarie Research **Equities**





(65) 6231 2981 (852) 3922 4075

Asia Research

Head of Equity Research	
Stephen O'Sullivan	(852) 3922 3566
Automobiles/Auto Parts	
Kenneth Yap (Indonesia)	(6221) 515 7343
Clive Wiggins (Japan)	(813) 3512 7856
Dan Lucas (Japan)	(813) 3512 6050
ES Kwak (Korea)	(822) 3705 8644
Linda Huang (Taiwan)	(8862) 2734 7521
Banks and Non-Bank Financ	
Ismael Pili (Asia) Nick Lord (Asia)	(813) 3512 5979 (852) 3922 4774
Sarah Wu (China)	(852) 3922 4774
Jemmy Huang (Hong Kong, Taiwan)	(8862) 2734 7530
Seshadri Sen (India)	(9122) 6653 3053
Ferry Wong (Indonesia)	(6221) 515 7335
Chan Hwang (Korea)	(822) 3705 8643
Michael Na (Korea)	(822) 2095 7222
Chin Seng Tay (Malaysia, S'pore)	(65) 6231 2837
Nadine Javellana (Philippines)	(632) 857 0890
Matthew Smith (Taiwan) Alastair Macdonald (Thailand)	(8862) 2734 7514 (662) 694 7741
, ,	(002) 094 7741
Chemicals/Textiles	(050) 2000 2574
Christina Lee (Hong Kong)	(852) 3922 3571 (9122) 6653 3040
Jal Irani (India) Sunaina Dhanuka (Malaysia)	(603) 2059 8993
	(003) 2039 0993
Conglomerates	(050) 0000 0557
Gary Pinge (Asia)	(852) 3922 3557
Leah Jiang (China) Kenneth Yap (Indonesia)	(8621) 2412 9020 (6221) 515 7343
Consumer	(0221) 313 7343
	(952) 2022 1111
Mohan Singh (Asia) Jessie Qian (China, Hong Kong)	(852) 3922 1111 (852) 3922 3568
Unmesh Sharma (India)	(9122) 6653 3042
Toby Williams (Japan)	(813) 3512 7392
HongSuk Na (Korea)	(822) 3705 8678
Edward Ong (Malaysia)	(603) 2059 8982
Alex Pomento (Philippines)	(632) 857 0899
Linda Huang (Taiwan)	(8862) 2734 7521
Emerging Leaders	
Jake Lynch (Asia)	(8621) 2412 9007
Minoru Tayama (Japan)	(813) 3512 6058
Robert Burghart (Japan)	(813) 3512 7853
Industrials	
Inderjeetsingh Bhatia (India)	(9122) 6653 3166
Christopher Cintavey (Japan)	(813) 3512 7432
Janet Lewis (Japan)	(813) 3512 7475
Chang Han Joo (Korea)	(822) 3705 8511
Sunaina Dhanuka (Malaysia) David Gambrill (Thailand)	(603) 2059 8993 (662) 694 7753
Insurance	(002) 00 1 1 1 00
Mark Kellock (Asia)	(852) 3922 3567
Seshadri Sen (Asia)	(9122) 6653 3053
Makarim Salman (Japan)	(813) 3512 7421
Media	,
Jessie Qian (China, Hong Kong)	(852) 3922 3568
Shubham Majumder (India)	(9122) 6653 3049
George Hogan (Japan)	(813) 3512 7851
Drem Jeanaiaeingam (Malayeia)	(603) 2050 8080

Oil and Gas Christina Lee (Hong Kong) Jal Irani (India) Polina Diyachkina (Japan) Edward Ong (Malaysia) Sunaina Dhanuka (Malaysia) Trevor Buchinski (Thailand) Pharmaceuticals	(852) 3922 3571 (9122) 6653 3040 (813) 3512 7886 (603) 2059 8982 (603) 2059 8993 (662) 694 7829	Adam Worthington (Asia) Carol Cao (China, Hong Kong) Kakutoshi Ohori (Japan) Prem Jearajasingam (Malaysia) Alex Pomento (Philippines) Commodities
Christina Lee (Hong Kong) Abhishek Singhal (India) Naomi Kumagai (Japan) Property Matt Nacard (Asia)	(852) 3922 3571 (9122) 6653 3052 (813) 3512 7474	Jim Lennon Max Layton Bonnie Liu Henry Liu Rakesh Arora Data Services
China, Hong Kong) Chris Cheng (China, Hong Kong) Unmesh Sharma (India) Hiroshi Okubo (Japan)	(852) 3922 373 (852) 3922 3573 (852) 3922 3581 (9122) 6653 3042 (813) 3512 7433	Andrea Clohessy (Asia) Eric Yeung Economics
Chang Han Joo (Korea) Tuck Yin Soong (Singapore) Elaine Cheong (Singapore) Corinne Jian (Taiwan) Patti Tomaitrichitr (Thailand)	(822) 3705 8511 (65) 6231 2838 (65) 6231 2839 (8862) 2734 7522 (662) 694 7727	Rajeev Malik (ASEAN, India) Richard Gibbs (Australia) Paul Cavey (China) Richard Jerram (Japan)
Resources / Metals and Mi Andrew Dale (Asia) Xiao Li (China) YeeMan Chin (China) Christina Lee (Hong Kong) Rakesh Arora (India) Adam Worthington (Indonesia)	(852) 3922 3587 (852) 3922 4626 (852) 3922 3662 (852) 3922 3571 (9122) 6653 3054 (65) 6231 2981	Martin Emery (Asia) Viking Kwok (Asia) George Platt (Australia) Tsumugi Akiba (Japan) Patrick Hansen (Japan) Strategy/Country
Polina Diyachkina (Japan) Technology	(813) 3512 7886	Daniel McCormack (Asia) Michael Kurtz (China)
Patrick Yau (Hong Kong) Zona Chen (Hong Kong) Damian Thong (Japan) David Gibson (Japan) George Chang (Japan) Michiko Kakiya (Japan) Yukihiro Goto (Japan) Michael Bang (Korea) Chia-Lin Lu (Taiwan) Daniel Chang (Taiwan) James Chiu (Taiwan) Nicholas Teo (Taiwan)	(852) 3922 1264 (852) 3922 3578 (813) 3512 7877 (813) 3512 7880 (813) 3512 7854 (813) 3512 7868 (813) 3512 5984 (822) 3705 8659 (8862) 2734 7526 (8862) 2734 7516 (8862) 2734 7517 (8862) 2734 7517	Seshadri Sen (India) Ferry Wong (Indonesia) David Gibson (Japan) Peter Eadon-Clarke (Japan) Chan Hwang (Korea) Prem Jearajasingam (Malaysia) Edward Ong (Malaysia) Alex Pomento (Philippines) Tuck Yin Soong (ASEAN, Singa Daniel Chang (Taiwan) Alastair Macdonald (Thailand)

(852) 3922 3565

(65) 6231 2842 (852) 3922 3634

(9122) 6653 3049

(6221) 515 7343

(813) 3512 7875

(603) 2059 8989

(852) 3922 4773

(852) 3922 5417

(852) 3922 3598

(813) 3512 7475

(822) 3705 8511

(822) 3705 8644

(603) 2059 8993

Macquarie:

Thomson:

Bloomberg:

Reuters:

Factset:

Kakutoshi Ohori (Japan) Prem Jearajasingam (Malaysia)	(813) 3512 7296 (603) 2059 8989
Alex Pomento (Philippines) Commodities	(632) 857 0899
Jim Lennon Max Layton Bonnie Liu Henry Liu Rakesh Arora Data Services	(4420) 3037 4271 (4420) 3037 4273 (8621) 2412 9008 (8621) 2412 9005 (9122) 6653 3054
Andrea Clohessy (Asia) Eric Yeung	(852) 3922 4076 (852) 3922 4077
Economics	
Rajeev Malik (ASEAN, India) Richard Gibbs (Australia) Paul Cavey (China) Richard Jerram (Japan)	(65) 6231 2841 (612) 8232 3935 (852) 3922 3570 (813) 3512 7855
Quantitative	
Martin Emery (Asia) Viking Kwok (Asia) George Platt (Australia) Tsumugi Akiba (Japan) Patrick Hansen (Japan) Strategy/Country	(852) 3922 3582 (852) 3922 4735 (612) 8232 6539 (813) 3512 7560 (813) 3512 7876
Daniel McCormack (Asia) Michael Kurtz (China) Seshadri Sen (India) Ferry Wong (Indonesia) David Gibson (Japan) Peter Eadon-Clarke (Japan) Chan Hwang (Korea) Prem Jearajasingam (Malaysia) Edward Ong (Malaysia) Alex Pomento (Philippines) Tuck Yin Soong (ASEAN, Singapore) Daniel Chang (Taiwan) Alastair Macdonald (Thailand)	(852) 3922 4073 (8621) 2412 9002 (9122) 6653 3053 (6221) 515 7335 (813) 3512 7880 (813) 3512 7850 (822) 3705 8643 (603) 2059 8989 (603) 2059 8982 (632) 857 0899 (65) 6231 2838 (8862) 2734 7516 (662) 694 7741
Find our research at	

www.macquarie.com.au/research

http://www.factset.com/home.aspx

www.thomson.com/financial

www.knowledge.reuters.com

MAC GO

Email macresearch@macquarie.com for access

Sales

Regional Heads of Sales

Prem Jearajasingam (Malaysia) Alex Pomento (Philippines)

(65) 6231 2888
(1 617) 598 2502
(41) 22 818 7712
(9122) 6653 3200
(9122) 6653 3200
(6221) 515 1555
(603) 2059 8888
(632) 857 0761
(1 212) 231 2527
(1 212) 231 2507
(1 212) 231 2848
(1 415) 835 1235

(603) 2059 8989 (632) 857 0899

Regional Heads of Sales cont'd

Angus Kent (Thailand)	(662) 694 7601
Michael Newman (Tokyo)	(813) 3512 7920
Charles Nelson (UK/Europe)	(44) 20 3037 4832
Rob Fabbro (UK/Europe)	(44) 20 3037 4865
Nick Ainsworth (Generalist)	(852) 3922 2010

Sales Trading

Nicholas Teo (Taiwan) **Telecoms**

Ramakrishna Maruvada (ASEAN)

Nathan Ramler (Japan) Prem Jearajasingam (Malaysia)

Transport & Infrastructure

Bin Liu (China) Shubham Majumder (India)

Kenneth Yap (Indonesia)

Anderson Chow (Asia)

Janet Lewis (Japan)

ES Kwak (Korea)

Jonathan Windham (Asia)

Chang Han Joo (Korea)

Wei Sim (China, Hong Kong)

Sunaina Dhanuka (Malaysia)

Tim Smart (Asia)

Adam Zaki (Asia)	(852) 3922 2002
Mike Keen (Europe)	(44) 20 3037 4905
Mona Lee (Hong Kong)	(852) 3922 2085
Brendan Rake (India)	(9122) 6653 3204
Stanley Dunda (Indonesia)	(6221) 515 1555

Sales Trading cont'd

Mario Argyrides (Korea)	(822) 3705 8610
Edward Robinson (London)	(44) 20 3037 4902
Matthew Ryan (Singapore)	(65) 6231 2888
Isaac Huang (Taiwan)	(8862) 2734 7582
Jon Omori (Tokyo)	(813) 3512 7838

Alternative Strategies

Convertibles - Roland Sharman	(852) 3922 2095
Depository Receipts - Robert Ansell	(852)3922 2094
Derivatives - Wayne Edelist	(852) 3922 2134
Futures - Tim Smith	(852) 3922 2113
Structured Products - Andrew Terlich	(852) 3922 2013